RPG Life Sciences Presents Investor Presentation for Q4 and FY26 Results
RPG Life Sciences reported Q4 FY26 revenue growth of 23.6% and PAT growth of 58.1% (excl. exceptional items). Full-year FY26 revenue reached ₹707.5 crore. The company is focused on scaling core brands, expanding its specialty portfolio, and strengthening its API business. ICRA reaffirmed its A+ rating.
The announcement includes detailed financial performance for the quarter and fiscal year, strategic priorities, and business segment updates, which are significant for investors and stakeholders.
The company has reported strong revenue and PAT growth for Q4 and FY26, with positive outlooks on its business segments and strategic initiatives. The reaffirmation of its credit rating further supports a positive sentiment.
RPG Life Sciences Limited has released its Investor Presentation detailing the financial results for the quarter ended March 31, 2026, and the full fiscal year. This presentation follows up on their previous intimation dated April 23, 2026.
The company highlighted a robust performance in Q4 FY26, with revenue from operations growing by 23.6% and EBITDA by 48.0% compared to Q4 FY25. Profit After Tax (PAT), excluding exceptional items, saw a significant increase of 58.1%. For the full fiscal year FY26, revenue from operations increased by 8.3% to ₹707.5 crore, while EBITDA grew to ₹172.7 crore and PAT (excluding exceptional items) stood at ₹111.7 crore.
Domestically, RPG Life Sciences continues to outperform the market, with its Domestic Formulations (DF) segment contributing 68.9% to total sales in FY26. The company is focusing on scaling core brands, building a stronger specialty and chronic portfolio, and enhancing salesforce productivity. The International Formulations (IF) segment contributed 17.6% to sales, with a focus on expanding global presence in emerging and select markets. The API business, contributing 13.5% to sales, was impacted by a fire incident but is focusing on new customer development and operational resilience.
RPG Life Sciences also provided an update on its business strategy, emphasizing product portfolio rejuvenation, strategic brand asset building, deepening customer coverage, and augmenting sales force effectiveness. The company is also investing in R&D and innovation, strengthening its API business, and expanding its global presence. They are also evaluating mergers and acquisitions as a growth driver and have a strong digital roadmap in place.
In terms of manufacturing and ESG initiatives, the company highlighted improvements in energy efficiency, water management, and waste management. They also reported an increase in women's deployment and employee well-being programs. The company's ICRA rating was reaffirmed at A+ with a stable outlook, and its short-term rating at A1, citing strong brands, steady growth, improving operating margins, and a robust capital structure.
Looking ahead, RPG Life Sciences aims to grow its immunosuppressant portfolio to over ₹200 crore and make Naprosyn a ₹100 crore+ brand. They are also focused on expanding their API business, strengthening customer relationships, and enhancing manufacturing productivity. The company has infused ₹140 crore in capex since FY22 to build modern plants and is evaluating opportunities for improving manufacturing productivity.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.